Markets:

Overview

News

Currencies

International

Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2602 -0.0001 (-0.04%)

Official Closing Price Updated: 8:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

April 29, 2024

Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 16, 2024

Via Benzinga

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation ↗

April 16, 2024

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

Via Benzinga

Who's Who In Cannabis: Latest Executive Changes You Should Know About ↗

April 15, 2024

Via Benzinga

IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury ↗

July 06, 2023

IGC Pharma, Inc. (AMEX: IGC) bagged a strategic investment

Via Benzinga

IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research

April 03, 2024

--News Direct--

Via News Direct

IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research ↗

April 02, 2024

Via Benzinga

EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success ↗

March 20, 2024

IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability...

Via Benzinga

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo ↗

March 20, 2024

IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed.

Via Benzinga

Benzinga's 2024 Virtual Healthcare: What's Next In Health? ↗

March 19, 2024

The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss...

Via Benzinga

IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

March 19, 2024

--News Direct--

Via News Direct

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 28, 2024

Via Benzinga

IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses ↗

February 19, 2024

IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy.

Via Benzinga

Topics Intellectual Property

Why IGC Pharma Stock Is Moving Higher ↗

January 23, 2024

IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to...

Via Benzinga

AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research ↗

November 21, 2023

IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency.

Via Benzinga

Topics Artificial Intelligence

Cannabis Based Pain Relief Solution Receives European Patent Approval ↗

October 20, 2023

IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain."

Via Benzinga

Topics Cannabis Intellectual Property

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 21, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 12, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 01, 2023

Via Benzinga

IGC Pharma FY23 Revenue Grows 129%, What About Net Loss? ↗

July 12, 2023

IGC Pharma, Inc. (AMEX:IGC) released its financial results for the fiscal year ended March 31, 2023, revealing revenue of $911,000, an increase of 129% compared to $397,000 in fiscal year 2022. FY 2023...

Via Benzinga

IGC Pharma Secures $12M Credit Facility From O-Bank To Aid Alzheimer's Research ↗

July 07, 2023

IGC Pharma, Inc. (AMEX: IGC) has recently secured a $12 million credit from the

Via Benzinga

IGC Pharma Secures $3M Via Private Placement ↗

July 06, 2023

IGC Pharma, Inc. (AMEX:IGC) announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited, an asset management firm with over $2 billion in...

Via Benzinga

Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket ↗

July 06, 2023

Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company.

Via Benzinga

12 Industrials Stocks Moving In Tuesday's Pre-Market Session ↗

June 27, 2023

Via Benzinga

IGC Announces Rebranding, Changes Name To IGC Pharma ↗

March 20, 2023

India Globalization Capital, Inc. (AMEX:IGC) announced it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better...

Via Benzinga

IGC Q3 2023 Revenue Grows 133% YoY, What About Net Loss? ↗

February 15, 2023

India Globalization Capital, Inc. (dba IGC, Inc.) (AMEX:IGC) released its third fiscal quarter 2023 financial results, revealing revenue of $332,000, a 133% increase compared to $142,000 in the Q3...

Via Benzinga

IGC Expanding Clinical Trials Of THC Based Drug Following Approval From Health Canada ↗

January 04, 2023

India Globalization Capital, Inc. (AMEX:IGC) has received a no objection letter from Health Canada for approval of its trial, “A phase 2, multi-center, double-blind, randomized, placebo-controlled...

Via Benzinga

IGC Starts Phase 2 Clinical Trials Of THC Based Drug Candidate For The Treatment Of Agitation In Dementia From Alzheimer's Disease ↗

December 01, 2022

India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants...

Via Benzinga

IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials ↗

November 02, 2022

India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

September 28, 2022

It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

IGC Pharma, Inc. Common Stock (NY:IGC)

Headline News about IGC Pharma, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today